MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$16,072K
Net Income
-$7,192K
Net Profit Margin
-44.75%
EPS
-$0.1
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
16,072
3,267
6,450*
8,153
Research and development
18,523
18,259
24,236*
20,002
General and administrative
6,354
6,581
7,594*
6,652
Gain on lease modification
-
-
408*
-
Impairment of long-lived assets
-
-
5,914*
0
Total operating expenses
24,877
24,840
37,336*
26,654
Loss from operations
-8,805
-21,573
-30,886*
-18,501
Interest income
1,609
1,742
2,649*
2,032
Other income (expense), net
5
-44
1,501*
620
Total other income, net
1,614
1,698
4,150*
2,652
Net loss
-7,191
-19,875
-26,736*
-15,849
Unrealized losses on marketable securities
-1
-157
-315
68
Total other comprehensive loss
-1
-157
-315*
68
Total comprehensive loss
-7,192
-20,032
-27,051
-15,781
Basic EPS
-0.1
-0.29
-0.43
-0.25
Diluted EPS
-0.1
-0.29
-0.43
-0.25
Basic Average Shares
70,629,419
69,540,075
62,932,625
63,029,293
Diluted Average Shares
70,629,419
69,540,075
62,932,625
63,029,293
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$7,192K
Interest income
$1,609K
Other income
(expense), net
$5K
Net loss
-$7,191K
Total other
comprehensive loss
-$1K
Total other income,
net
$1,614K
Loss from operations
-$8,805K
Unrealized losses on
marketable securities
-$1K
Collaboration revenue
$16,072K
Total operating
expenses
$24,877K
Research and development
$18,523K
General and
administrative
$6,354K
Buy us a coffee
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)